Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 21, 2017
What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?
PAR PHARM has two hundred and twelve approved drugs.| Patents: | 1 |
| Tradenames: | 124 |
| Ingredients: | 121 |
| NDAs: | 212 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Par Pharm | METAPROTERENOL SULFATE | metaproterenol sulfate | TABLET;ORAL | 072025-001 | Jun 28, 1988 | RX | No | Yes | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Par Pharm | PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE | amitriptyline hydrochloride; perphenazine | TABLET;ORAL | 070595-001 | Sep 11, 1986 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Par Pharm | METHYLDOPA AND CHLOROTHIAZIDE | chlorothiazide; methyldopa | TABLET;ORAL | 070783-001 | Nov 6, 1987 | DISCN | No | No | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Par Pharm | DILTIAZEM HYDROCHLORIDE | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 074984-001 | Dec 20, 1999 | AB3 | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Par Pharm | IMIPRAMINE HYDROCHLORIDE | imipramine hydrochloride | TABLET;ORAL | 089422-001 | Jul 14, 1987 | AB | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-007 | Jun 13, 1995 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-004 | Jun 13, 1995 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-001 | Approved Prior to Jan 1, 1982 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-007 | Jun 13, 1995 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
cyanocobalamin | Nasal Spray | 500 mcg/spray | NASCOBAL | 4/28/2017 |
zafirlukast | Tablets | 10 mg and 20 mg | ACCOLATE | 2/29/2008 |
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 1948613 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2605413 | ► Subscribe | |||||||||||||||||||||||||||
| Mexico | 2007013118 | ► Subscribe | |||||||||||||||||||||||||||
| China | 101163679 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 5378788 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB11/015 | United Kingdom | ► Subscribe | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 | ||||||||||||||||||||||||||
| 315 | Luxembourg | ► Subscribe | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE | ||||||||||||||||||||||||||
| 12/033 | Ireland | ► Subscribe | PRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN | ||||||||||||||||||||||||||
| 0443983/03 | Switzerland | ► Subscribe | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 | ||||||||||||||||||||||||||
| C0031 | Belgium | ► Subscribe | PRODUCT NAME: ZAFIRLUKAST; NAT. REGISTRATION NO/DATE: 624 S 295 F 3 19961216; FIRST REGISTRATION: IE PA 51/67/1 19960103 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,371 others who get our Drug Patent Expiration Alerts:
